Kestra Investment Management LLC Takes $541,000 Position in Royalty Pharma PLC $RPRX

Kestra Investment Management LLC acquired a new stake in Royalty Pharma PLC (NASDAQ:RPRX) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm acquired 13,992 shares of the biopharmaceutical company’s stock, valued at approximately $541,000.

Several other hedge funds also recently modified their holdings of RPRX. Capital International Investors grew its holdings in shares of Royalty Pharma by 24.4% in the 3rd quarter. Capital International Investors now owns 27,212,694 shares of the biopharmaceutical company’s stock valued at $960,064,000 after acquiring an additional 5,332,074 shares in the last quarter. Dorsey Asset Management LLC bought a new position in shares of Royalty Pharma in the 3rd quarter valued at about $82,924,000. Qube Research & Technologies Ltd grew its holdings in shares of Royalty Pharma by 737.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 2,481,771 shares of the biopharmaceutical company’s stock valued at $87,557,000 after acquiring an additional 2,185,366 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Royalty Pharma by 379.2% in the 3rd quarter. Millennium Management LLC now owns 2,235,133 shares of the biopharmaceutical company’s stock valued at $78,855,000 after acquiring an additional 1,768,702 shares in the last quarter. Finally, Clark Capital Management Group Inc. bought a new position in shares of Royalty Pharma in the 3rd quarter valued at about $61,805,000. Institutional investors own 54.35% of the company’s stock.

Royalty Pharma Trading Up 0.2%

Royalty Pharma stock opened at $53.97 on Thursday. Royalty Pharma PLC has a 52 week low of $32.29 and a 52 week high of $54.74. The company has a debt-to-equity ratio of 0.86, a quick ratio of 2.66 and a current ratio of 2.66. The stock has a market capitalization of $31.08 billion, a P/E ratio of 36.71, a PEG ratio of 1.48 and a beta of 0.40. The stock has a 50-day simple moving average of $49.52 and a 200 day simple moving average of $44.27.

Royalty Pharma (NASDAQ:RPRX) last posted its quarterly earnings results on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping analysts’ consensus estimates of $1.22 by $0.08. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%.The business had revenue of $631.00 million during the quarter, compared to analysts’ expectations of $881.69 million. Analysts expect that Royalty Pharma PLC will post 5.05 earnings per share for the current year.

Royalty Pharma Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Investors of record on Friday, May 15th will be issued a dividend of $0.235 per share. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. Royalty Pharma’s dividend payout ratio (DPR) is presently 63.95%.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on RPRX shares. Wall Street Zen upgraded Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. The Goldman Sachs Group restated a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Weiss Ratings cut Royalty Pharma from a “buy (b)” rating to a “buy (b-)” rating in a report on Friday, May 15th. Citigroup raised their price objective on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Finally, Morgan Stanley lifted their price target on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a report on Friday, April 10th. Seven analysts have rated the stock with a Buy rating, According to MarketBeat, Royalty Pharma presently has an average rating of “Buy” and a consensus target price of $53.71.

Insider Buying and Selling

In related news, CFO Terrance P. Coyne sold 34,791 shares of Royalty Pharma stock in a transaction dated Tuesday, April 28th. The stock was sold at an average price of $49.78, for a total transaction of $1,731,895.98. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the firm’s stock in a transaction that occurred on Thursday, May 14th. The stock was sold at an average price of $53.06, for a total transaction of $726,073.04. Following the sale, the executive vice president owned 31,881 shares of the company’s stock, valued at $1,691,605.86. This trade represents a 30.03% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 169,577 shares of company stock worth $8,234,191. Company insiders own 18.84% of the company’s stock.

About Royalty Pharma

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.